The present study was supported by a grant from Biotest Pharma (Dreieich, Germany). We thank A. Möricke for skilful technical assistance.
) and IgM (•) purified from Pentaglobin (batch no. 1461073). The purified immunoglobulins were added to the wells at dilutions yielding optimal ELISA reactivity (2 mg/ml for IgG and 0·5 mg/ml (more ...)
DISCUSSION Beneficial effects of polyvalent immunoglobulins have been demonstrated in animal models of sepsis. However, most of these studies have also shown that such effects are most pronounced when IVIG is given either before or very early after bacterial challenge [17, 24, 25]. In humans, treatment of established sepsis with IVIG has yielded controversial results, a fact that may be due to the heterogeneity of causative organisms and the variation in underlying diseases and clinical status of the patients included in such studies (review in [26, 27]). Recently, it has been suggested that a careful stratification of patients with respect to their Acute Physiology and Chronic Health Evaluation (APACHE) and sepsis scores or the demonstration of endotoxaemia may lead to more conclusive results [27, 28]. At least in Europe, variations of antibody levels in the raw material of IVIG may play a lesser role in the outcome of clinical studies, because the European Pharmacopoeia prescribes the inclusion of plasma units from ≥1000 donors per batch [29].
The potential effect of IVIG in established sepsis may be related to its recently discovered ability to inhibit the release of proinflammatory mediators [30]. Inhibition by IVIG of tumour necrosis factor-alpha (TNF-α) and IL-1 release from monocytes has been linked to the presence of anti-LPS antibodies in polyclonal immunoglobulin [30]. Our own data show that this inhibitory effect was stronger for an IgM-enriched IVIG preparation compared with ‘pure’ IgG products, which may point to a higher concentration (or avidity) of endotoxin-neutralizing antibodies in the IgM class [31]. We therefore decided to measure quantitatively the level of LPS-specific antibodies in IgM-containing versus conventional IVIG products.
A drawback of previous studies examining the anti-LPS antibody content of IVIG was that either the O antigens examined were poorly defined, or that antibody concentrations were reported in arbitrary units, which precluded a comparison with antibody levels known to be protective from animal models of sepsis [17, 32–35]. In the present study, we used a previously described quantitative ELISA system [17, 18] to quantify the level of O antigen-specific IgG and IgM antibodies in four commercial IVIG preparations. Purified LPS preparations were obtained from those O antigen serotypes that have been identified most frequently among isolates causing Gram-negative septicemia. For E. coli, various seroepidemiological studies were available which showed that, of the more than 150 known O serotypes, the O antigens O1, O2, O4, O6, O8, O15, O16, O18 and O75 account for >80% of the antigenic types causing septicaemia [36–40]. When the data from the last-mentioned studies were pooled, the O6 antigen of E. coli occurred most frequently (11·9% of septicaemia cases), while the other indicated antigens each accounted for 6–8% of cases [36–40]. Studies of the seroepidemiology of bacteraemic P. aeruginosa isolates showed that Fisher-Devlin serotypes 1–5 were predominant in this setting [41, 42]. In the study of Vásquez et al., Fisher-Devlin serotype 1 (corresponding to international type (IATS) type 6) was found in 50%, Fisher-Devlin type 2 (IATS 11) in 24·3%, and Fisher-Devlin type 3 (IATS 2) in 11·4% of bacteraemic isolates [42]. Recently, we examined the distribution of Klebsiella O serotypes in clinical material and found that the O serotypes O1, O2ab and O3 accounted for 36·7%, 12·7% and 30·4% (together, 79·8%) of bacteraemic isolates, respectively [43]. Thus, the panel of enterobacterial and Pseudomonas LPS preparations used in the present study comprises a significant portion of the O antigen serotypes associated with septicaemia.
All products tested contained specific IgG antibodies against the LPS antigens included in the study (Table 2). The differences of antibody levels against specific LPS antigens may be explained by different frequencies in which strains of individual O serotypes occur in the gut flora of the plasma donor populations. Furthermore, after having colonized the gut, strains carrying different O antigens may also differ in their ability to translocate to the mesenteric lymph nodes and stimulate an LPS-specific humoral immune response [44, 45]. The view that the presence of natural antibodies in human serum is related to (transient or stable) intestinal colonization is substantiated by our finding that none of the immunoglobulin preparations contained detectable antibody against LPS derived from V. cholerae, an organism that does not usually colonize the human gut, at least in the Mid-European and North-American donor populations from which the plasma units used for commercial immunoglobulin production are obtained.
The main goal of the present study was to elucidate whether an enrichment of IgM antibodies, which is part of the specific production process of Pentaglobin, correlates with an enrichment of LPS-specific antibody. This was suggested by the results of Jackson et al., who tested a single batch of Pentaglobin against a pool of four LPS antigens and found that the anti-LPS IgM titre was 1/1024, compared with an IgG titre of 1/32 [14]. Also, after infusion of this product in bone marrow transplant patients, LPS-specific IgM levels rose significantly, in contrast to an insignificant rise of anti-LPS IgG levels [14]. Our data confirmed and extended these findings for a total of 14 LPS serotypes. Although Pentaglobin contains no more than 12% IgM, compared with 75% IgG, antibody levels measured in the IgM fraction of the various batches were as high or even higher compared with those found in the corresponding IgG fraction (Table 3). When values were corrected for total immunoglobulin content in grams, LPS-specific antibodies appeared to be enriched by a factor of 3·9–21·3 in the IgM fraction (Table 5). The calculation of the ratios given in this Table was performed on a weight basis and the results expressed as μg/g of total immunoglobulin; however, identical figures would result if ratios were expressed as micromoles of antibody per moles of total immunoglobulin.
In view of these findings, it seems noteworthy that early studies by Rosen and coworkers showed that ‘natural’ antibodies against Gram-negative bacteria were associated with the 19S (IgM) fraction of normal human sera [46–48]. In the study of Michael & Rosen, an IgM preparation obtained from Cohn fraction III had significantly higher opsonic and protective activity in an animal model of Gram-negative sepsis compared with the corresponding IgG fraction [46]. These early studies did not examine antigenically well defined strains, but our data show that antibodies belonging to the IgM fraction comprise specificities directed against many clinically relevant O antigen serotypes.
A novel finding of this study was the observation that antibodies in both IgG and IgM products were directed against O side chain determinants. All preparations produced stepladder-like reaction patterns on immunoblots typical of O side chain-reactive antibodies. Our ELISA experiments showed little or no antibody activity against LPS prepared from rough mutant strains such as E. coli J5 in most of the batches (Table 2). However, since subsequent immunoblotting studies revealed the presence of such antibodies in the IgG products (Fig. 3), it is possible that the direct ELISA system is not optimally suited to detect such antibodies. In future studies, the use of capture molecules such as polymyxin B [49] or poly-l-lysine [50] may enhance the detection of rough mutant antibodies.
The question whether IgG and IgM, when infused together, will compete for LPS recognition in vivo cannot be answered by this study. Our ELISA experiments show that both immunoglobulin classes are able to compete with each other in vitro. Both classes contain specific antibody which appears to have the same avidity for LPS (Fig. 4). When Pentaglobin is infused to septic patients, competition effects are less likely to occur because LPS is distributed widely throughout the vascular system. IgG and IgM antigen contacts may therefore occur at separate sites in the bloodstream compared with the situation on the ELISA plate, where both classes of antibody compete for antigen concentrated on a minimal area of contact. To our knowledge, clinical deterioration of septic patients related to the infusion of Pentaglobin has never been described.
Taken together, the present data show that IVIG preparations contain significant levels of LPS-specific antibodies directed against various clinically relevant O antigen serogroups of Gram-negative species. Such antibodies are concentrated in the IgM fraction of the IgM-enriched product by a factor of 3·9–21·3. Since antibodies of the IgM class have been suggested to be the most important in the neutralization and clearance of endotoxin [51], further experimental and clinical studies employing IgM-enriched preparations of IVIG are clearly warranted.
The present study was supported by a grant from Biotest Pharma (Dreieich, Germany). We thank A. Möricke for skilful technical assistance.